Fisher & Paykel Healthcare Corporation Limited logo

Fisher & Paykel Updates Revenue & Earnings Guidance

Guidance20 February 2020FPHHealthcare

News Release
STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)


Fisher & Paykel Healthcare updates revenue and earnings guidance on stronger Hospital

and Homecare sales


Auckland, New Zealand, 21 February 2020 - Fisher & Paykel Healthcare Corporation Limited

announced today that it has updated its revenue and earnings guidance for the financial year

ended 31 March 2020.


The full year guidance previously provided in November, based on a NZ:US exchange rate of

64 cents, was for operating revenue to be approximately $1.19 billion and net profit after tax to

be approximately $255 million to $265 million.


Now, assuming a NZ:US exchange rate of approximately 64 cents for the balance of the

financial year, the company expects full year operating revenue to be approximately $1.2 billion

and net profit after tax to be in the range of approximately $260 million to $270 million.


“We’ve seen better-than-expected sales in our Homecare product group combined with

continued strong growth in our Hospital product group. This includes an increase in demand

from China related to the COVID-19 coronavirus outbreak,” said Lewis Gradon, Managing

Director and CEO.


Coronavirus impact


Mr Gradon said the company has received inquiries about possible impacts to the company’s

supply chain resulting from coronavirus. Fisher & Paykel Healthcare does not have a

manufacturing facility in China; however, some of its suppliers of raw materials are based in

China.


“At this stage, we do not anticipate any significant impact on supply to our existing customers.

We will continue to assess this on an ongoing basis, particularly if the outbreak escalates or

continues for a prolonged period,” said Mr Gradon.


“During this challenging time for China, we appreciate the efforts of our own team and our

suppliers. Our people have been working long hours to ship products quickly, assemble them,

and meet the need for training, particularly in Wuhan. Many of our suppliers have expedited the

supply of raw materials to us as a manufacturer of essential medical devices, and we are

deeply grateful for that,” he said.


About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and

systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep

apnea. The company’s products are sold in over 120 countries worldwide. For more information

about the company, visit our website www.fphcare.com.


Ends


Media & Investor Contacts:

Karen Knott

Senior Communications Manager

karen.knott@fphcare.co.nz

+64 (0) 21 713 911

Hayden Brown

Investor Relations Manager

hayden.brown@fphcare.co.nz

+64 (0) 27 807 8073

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.

Other issuers discussed similar conditions around this time

Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.

  • PFI — Property for Industry Limited: COVID-19 Update and Q1 Dividend
    2020-05-07

    NZX and media announcement — 8 May 2020 COVID-19 UPDATE AND Q1 DIVIDEND Property for Industry Limited (PFI, the Company) has today provided an update on the impact of the COVID-19 virus on the Company and announced a first quarter dividend of 1.8000 cents per…”

  • PFI — Property for Industry Limited: COVID-19 and 2020 Guidance Update
    2020-04-15

    NZX and media announcement — 15 April 2020 COVID-19 AND 2020 GUIDANCE UPDATE Property for Industry Limited (PFI, the Company) has today provided an update on the impact of the COVID-19 virus on the guidance provided by the Company. PFI announced its 2019 an…”

  • AFT — AFT Pharmaceuticals Limited: Market Trading Update
    2020-03-10

    AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com Market and media release 10 March 2020 AFT Pharmaceuticals trading updat…”